Provided by Tiger Trade Technology Pte. Ltd.

Rallybio Corp.

8.87
-0.2200-2.42%
Post-market: 8.870.00000.00%16:10 EDT
Volume:145.80K
Turnover:1.34M
Market Cap:46.84M
PE:-5.58
High:9.47
Open:9.00
Low:8.87
Close:9.09
52wk High:11.49
52wk Low:1.76
Shares:5.28M
Float Shares:2.54M
Volume Ratio:1.06
T/O Rate:5.74%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5900
EPS(LYR):-1.5948
ROE:-15.01%
ROA:-31.70%
PB:0.81
PE(LYR):-5.56

Loading ...

Rallybio Announces Positive Data for Rlyb116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement

THOMSON REUTERS
·
Feb 17

Rallybio Corp - Rlyb116 Doses Well Tolerated With No Gi Side Effects

THOMSON REUTERS
·
Feb 17

NASDAQ TRADE HALT REASON NOT AVAILABLE AT 03:58 AM

Reuters
·
Feb 06

Rallybio Corp trading halted, news pending

TIPRANKS
·
Feb 06

BRIEF-Rallybio Announces Reverse Stock Split Of Common Stock

Reuters
·
Feb 04

Rallybio führt Aktiensplit im Verhältnis 1:8 durch

Reuters
·
Feb 04

Rallybio Corp - to Effect One-for-Eight Reverse Stock Split

THOMSON REUTERS
·
Feb 04

Rallybio Shareholders Approve Reverse Stock Split Amendment

TIPRANKS
·
Jan 30

Rallybio Corporation Held Special Shareholder Meeting

Reuters
·
Jan 30

Rallybio Terminates Phase 2 FNAIT Pregnancy Study: What Investors Need to Know

TIPRANKS
·
Jan 14

Rallybio’s Phase 2 FNAIT Prevention Study Reaches Completion: What Investors Should Watch Next

TIPRANKS
·
Jan 10

Rallybio Corporation Announces Date for Upcoming Special Stockholders Meeting

Reuters
·
Dec 24, 2025

Rallybio Corporation Reports Strong Q3 2025 Results

TIPRANKS
·
Nov 07, 2025

UPDATE: Rallybio Q3 Adj. EPS $(0.14) Beats $(0.21) Estimate, Sales $212.000K Beat $66.667K Estimate

Benzinga
·
Nov 06, 2025

Rallybio posts Q3 net income of $16 million

Reuters
·
Nov 06, 2025

BRIEF-Rallybio Q3 Net Income USD 16.016 Million

Reuters
·
Nov 06, 2025

Rallybio Corp - Cash Runway Extended Through 2027

THOMSON REUTERS
·
Nov 06, 2025

Rallybio Corp - Net Loss $0.36 per Common Share for Q3

THOMSON REUTERS
·
Nov 06, 2025

Rallybio’s RLYB116 Study: A Potential Game-Changer in Hematologic and Autoimmune Disease Treatment

TIPRANKS
·
Oct 28, 2025

Rallybio Completes Dosing of First Cohort in Rlyb116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study

THOMSON REUTERS
·
Sep 25, 2025